Waldencast plc operates as a global multi-brand beauty and wellness platform built around Obagi Medical and Milk Makeup. News about WALD commonly covers brand-level product launches, physician-dispensed skincare, cosmetics, suncare, and aesthetic offerings, including Obagi's advanced skincare products and Obagi® saypha® MagIQ™ hyaluronic acid filler.
Company updates also include quarterly and annual financial results, segment performance, channel and distribution developments, clinical-evidence collaborations for aesthetic products, supply-chain and credit-facility actions, and governance or reporting matters tied to financial restatements, internal control over financial reporting, and regulatory review.
Waldencast (WALD) reported first-half 2026 results, including a 57.1% decline in revenue from continuing operations. Revenue fell to $26.1 million from $60.9 million a year earlier, while the continuing-operations net loss widened to $94.9 million from $48.3 million. Milk Makeup recorded a $14.8 million adjusted EBITDA loss, compared with $9.7 million in adjusted EBITDA a year earlier, and a $52.3 million goodwill impairment.
The July 30 sale of Obagi Medical to Bridgepoint, valued at up to $460 million, yielded $149.9 million in net cash proceeds after repayment of $178.4 million in Lumina debt. Cash from continuing operations stood at $138.6 million on August 31. The board approved a Nasdaq delisting, and Waldencast intends to seek over-the-counter quotes. The company estimates it can eliminate 80% to 90% of its $18.5 million in 2025 recurring headquarters costs on an annual run-rate basis over the next eight to twelve months.
Waldencast (WALD) filed Form 25 on September 24, 2026, to remove its shares and warrants from Nasdaq.
The filing covers its Class A ordinary shares and redeemable warrants. Each whole warrant is exercisable for one Class A share at $11.50. Waldencast expects the last day of Nasdaq trading to be on or about October 2, 2026, and delisting to take effect on or about October 4, 2026. Deregistration under Section 12(b) is expected 90 days after the Form 25 filing.
Waldencast intends to file Form 15 on or about October 5, 2026. Filing it would immediately suspend the company’s obligation to submit periodic SEC reports, including Forms 20-F and 6-K.
Waldencast (WALD) will voluntarily delist its Class A ordinary shares and warrants from Nasdaq and deregister these securities under the Exchange Act, with a Form 25 filing expected on or about September 24, 2026 and the last Nasdaq trading day anticipated on or about October 2, 2026.
The company plans to file a Form 15 on or about October 5, 2026, which will immediately suspend its obligation to file periodic SEC reports, with Section 12(b) deregistration expected to become effective 90 days after the Form 25 filing. The Board cites high U.S. listing and compliance costs, management time demands, limited trading volume and float, and reduced reliance on U.S. equity markets after paying down debt with Obagi-related proceeds as key reasons. In 2025, central headquarters costs were $18.5 million, a substantial portion of which is expected to be eliminated. Following the Obagi Medical sale, the Board will also seek shareholder approval to rename the company Milk Makeup plc and intends, if approved, to pursue over-the-counter quotation under the ticker “MLKM”.
Waldencast (NASDAQ: WALD) has completed the previously announced sale of its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint in a transaction valued at up to $460 million, subject to negotiated deductions and customary closing adjustments. The company has repaid all of its outstanding senior term loan facility in conjunction with the closing and will focus on accelerating the global growth of its remaining brand, Milk Makeup.
Founders Michel Brousset and Hind Sebti, together with CFO Manuel Manfredi, will leave Waldencast to lead Obagi Medical alongside Bridgepoint. Executive Chairman Felipe Dutra will act as Waldencast’s principal executive officer and principal financial officer, while the Board will review any further allocation of transaction proceeds.
Waldencast (NASDAQ: WALD) announced FDA approval of Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio. The product, developed with Croma-Pharma MACRO Core Technology, is indicated for cheek augmentation and correction of midface contour deficiencies in adults over 21.
The approval follows the U.S. launch of Obagi saypha MagIQ and supports Obagi’s strategy in the growing dermal filler market. According to Obagi, interim ALOHA Program data show 94% of injectors view MagIQ as complementary to current fillers, with 42.6% of practices evaluating Obagi skincare.
Waldencast (NASDAQ: WALD) agreed to sell its Obagi Medical dermatological skincare and aesthetics business to Bridgepoint for an enterprise value of up to $460 million. The deal supports Waldencast’s plan to repay about $178 million of senior secured term debt and sharpen focus on Milk Makeup.
Bridgepoint will acquire 100% of Obagi Medical’s equity. Founders Michel Brousset and Hind Sebti and selected managers will depart Waldencast to lead Obagi Medical. Closing is expected in Q3 2026, subject to regulatory approvals, with no financing condition or shareholder vote.
Obagi Medical (NASDAQ: WALD), part of Waldencast, shared new clinical and real-world data at the Music City SCALE meeting. Highlights include interim results from the ALOHA real-world evaluation of Obagi Saypha MagIQ filler and first data from the NU-GEN Cellular Renewal Serum clinical program.
The ALOHA interim data show 94% of injectors believe MagIQ complements existing fillers, with 43% of patients also evaluating Obagi skincare. NU-GEN is clinically proven to visibly rewind skin’s age by up to six years while addressing nine signs of aging.
Waldencast (NASDAQ: WALD) brand Obagi Medical has partnered with health optimization company Next Health to launch “The Skin Recharge Station,” a multi-city pop-up truck experience merging advanced skincare and longevity-focused wellness.
The May 2026 tour in California highlights NAD+ science, Obagi’s NU-GEN Cellular Renewal Serum, Aura skin analysis, and chances to win Next Health NAD+ shots and IV drips.
Obagi Medical (NASDAQ: WALD) launched Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40 on April 30, 2026. The product is a 100% mineral-filter sunscreen formulated with antioxidants, ceramides, and squalane for sensitive, acne-prone, and post-procedure skin.
It is dermatologist-tested, described as lightweight and non-comedogenic, and is priced at $65, available on Obagi.com, Amazon, authorized providers, and select retailers.
Waldencast (NASDAQ: WALD) announced on April 28, 2026 that the SEC has concluded its investigation related to Waldencast's restatement and historical accounting practices at Obagi Cosmeceuticals.
Based on available information, the SEC does not intend to recommend enforcement action. The company said it fully cooperated and incurred substantial legal and advisory costs.